DBVT DBV Technologies S.A. - America

33.25
-0.47  -1%
Previous Close 33.72
Open 33.89
Price To book 6.27
Market Cap 1.53B
Shares 46,000,000
Volume 74,144
Short Ratio 3.58
Av. Daily Volume 77,988

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 completion of enrollment announced March 10, 2017. Data due 2H 2017.
Viaskin Peanut (REALISE)
Peanut allergy
Phase 1/2 data due 2H 2017.
Viaskin Milk
Cow’s milk protein allergy (CMPA)
Phase 3 completion of enrollment announced March 10, 2017. Data due 2H 2017.
Viaskin Peanut (PEPITES)
Peanut allergy

Latest News

  1. DBV Technologies : Ordinary and Extraordinary General Meeting of June 15, 2017 Procedures for Obtaining Preparatory Documents for the General Meeting
  2. DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company
  3. DBV Technologies Highlights Research Presentation of EPIT® for the Treatment of Crohn's Disease at Digestive Disease Week 2017
  4. DBV Technologies to Attend Upcoming Investor Conferences
  5. DBV Technologies Reports March 31, 2017 Cash Position
  6. DBV Technologies to Attend the 10th Kempen Life Sciences Conference
  7. DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination
  8. DBV Technologies : Announces Filing of its 2016 "Document de Référence" and Annual Report on Form 20-F
  9. DBV Technologies Reports Full Year 2016 Financial Results
  10. DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children
  11. 7 Stocks Trending Up With Monster Volume
  12. DBV Technologies :Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children
  13. A patch could fix your peanut-allergy problem
  14. DBV Technologies Reports December 31, 2016 Cash Position
  15. DBV to Present Data at the 2017 AAAAI Meeting Highlighting the Therapeutic Potential of EPIT®
  16. DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis